99bet reclame aqui President-elect Donald Trump continues to promise a mass deportation effort when he returns to the White House, but questions remain about how such a policy would affect the Texas workforce. According to the Pew Research Center, nearly 5% of the American workforce consists of undocumented immigrants. In Texas, that number is even higher, with undocumented workers making up 8% of the state’s workforce, totaling more than 1 million individuals. Many of these workers are employed in essential industries, including farming, construction, meatpacking, housekeeping, landscaping and restaurant services. Jon Taylor, a professor of political science at the University of Texas at San Antonio, said mass deportation is a controversial issue, with supporters arguing for stricter immigration policies. One such supporter is Texas State Rep. David Spiller, who represents an area near Fort Worth. “The federal government has identified that about two-thirds of those arrested on federal charges in our country are here illegally,” Spiller said. But if a mass deportation, like the one President Trump has promised, goes forward, the impact on Texas’ workforce could be severe. “It would cripple the Texas economy,” Taylor warned. “There are estimates that Texas would be hit harder than most other states.” Taylor noted that industries reliant on immigrant labor, such as construction and hospitality, may resist mass deportation policies. The rapid growth of cities along the I-35 corridor between San Antonio and Austin could face significant disruption. “We’ve already begun to see some pushback from agricultural interests, particularly in Texas, questioning whether the scope of deportations being promised would harm the state’s agricultural sector,” Taylor said. While the full impact of such policies remains uncertain, Taylor emphasized that the only way to know the consequences is to see them unfold. “If migrants in key industries are suddenly deported, it could lead to a much slower approach to enforcement,” Taylor concluded. As the nation waits to see how Trump’s mass deportation plan develops, Texas’ workforce, particularly in sectors heavily reliant on immigrant labor, faces an uncertain future.Husband’s excessive manners leave wife feeling left behind

Newby has 18 as UNC Wilmington defeats Marshall 78-69All of the strikes at European airports this winter – find out if you are affected

A desperate confession in my group chat shows the 'mummy cocaine' trend has gone too far. JANA HOCKING reveals what this very middle-class epidemic has done to the women she once adored By JANA HOCKING FOR DAILY MAIL AUSTRALIA Published: 13:42, 29 December 2024 | Updated: 13:53, 29 December 2024 e-mail View comments Confession time: Last week, I took the 'Peter Pans of Sydney ' to task over their rampant cocaine use , arguing they're far too old to still be risking their health and relationships for a few hours of 'fun' on the weekends. The response was interesting. Yes, I had many women (and men) flooding my DMs to say I was absolutely right. I also had my fair share of abuse from misogynistic little cokeheads who didn't like me pointing out that cocaine causes erectile dysfunction. But then, I was also reminded to look at my own backyard. In focusing on how coke had wrecked a generation of men, I had neglected the women over 40 who are also hopelessly hooked on the stuff. And there are plenty of them doing lines at nightclubs with strangers every single weekend while their poor husbands look after the children at home . It's time to correct the record . I'll always hold my own sex accountable (myself included) so it's only fair I dish the dirt on what it's like on the other side of the fence. Let's start with a Sunday morning that, sadly, wasn't too long ago. I woke up feeling that familiar dread - an emotional hangover paired with a muted sadness. My mouth tasted like the remnants of last night's dirty martinis, and I anxiously scrolled through my texts and Instagram to make sure I hadn't sent or posted anything regrettable. 'Thank God,' I thought as it all came up clear. Then the messages started pinging in on a WhatsApp group created by some new girlfriends. I felt a slightly terrible sense of relief as I realised a few of them were waking up with worse anxiety than my silly little hangover. 'Oh, God. I spent $600 last night just on coke!' wrote one of them, subtly hinting that others who had partaken in her 'party favours' might want to chip in. In focusing on how coke had wrecked a generation of men, I had neglected the women over 40 who are also hopelessly hooked on the stuff, writes Mail+ columnist Jana Hocking Jana (left) was neck deep in the Sydney party scene in the 2010s, when Instagram was new and cocktails didn't cost $25. But many women of her generation are still partying like they're in their twenties and thirties Suddenly, my $120 bar tab seemed like nothing in comparison. A hangover I could handle. A cocaine comedown at my age? No, thank you. I've got deadlines to meet and serotonin reserves I'm clinging onto for dear life. It made me realise something: many of the women I once admired - glamorous, carefree, unstoppable forces of the social scene - are still chasing the same highs they did in their twenties. We all know that one woman at a party desperately asking if we've seen any blokes with 'a bag'. Sure, it may have been cute to flirt with a guy for a cheeky line when you were young and single, but now it just looks desperate. I don't think it takes a rocket scientist to figure out that now the stakes are higher, and the consequences are etched into these women's faces. Botox appointments are becoming more frequent, not just to fend off natural ageing but to repair the wear and tear of years spent trying to keep up. Take Fiona, for example (name changed, of course). She's a real estate agent in her forties who swears by the 'one line, one dance floor' rule she has followed since 1999. But when I saw her at a Christmas party, I barely recognised her. The spark in her eyes had dimmed, her laugh sounded strained, and her famous cheekbones looked hollow. Over a few glasses of wine, she confessed, 'It's not just once in a while anymore. I think I've forgotten how to have fun without it.' Then there's the alarming trend of women using cocaine as a weight-loss drug in lieu of Ozempic. The so-called 'miracle' injections might be all over the headlines, but their high price and limited availability have driven some women to a more dangerous (and illegal) alternative. 'It curbs your appetite and gives you energy,' one woman whispered at a lunch, as though sharing a life hack. But the reality is very different. Regular cocaine use not only wreaks havoc on your body but also creates a dependency that's hard to escape. The irony is bitter: women are striving for health and vitality (I blame you, Gwyneth Paltrow, and all your Goop glowiness!) but are using a method that is about as far from Goop's kooky wellness philosophy as you can get. They are destroying their bodies from the inside out. As one friend who finally quit put it, 'I wanted to look my best, but I ended up feeling my worst.' And honestly, why would we willingly pile more stress on our bodies? Being a woman in your early forties is tough. Between PMS and the mood swings of perimenopause, we've already got enough emotional chaos to contend with. Why add to that the dreaded Tuesday Blues from a weekend 'on the bags'? No, thanks. I don't think it takes a rocket scientist to figure out that now the stakes are higher, and the consequences of weekend cocaine binges are etched into these women's faces (stock image) Read More What cocaine has done to the men of my generation is tragic. These are their terrifying confessions Take Amelia, a divorcee in her fifties who recently re-entered the dating world. 'It's just to keep up,' she told me over coffee, explaining her new boyfriend's love of 'kicking on' after a night out had made her revisit her long-abandoned cocaine habit. But the toll was obvious - her radiant complexion had given way to visible exhaustion. And her tales of wild nights? They weren't romantic escapades but cringeworthy stories of lost phones, awkward apologies to babysitters, and comedown-induced arguments. One of the saddest revelations came from Claire, a mother of two who admitted her 'mummy's little helper' wasn't just the odd glass of rosé. 'It started with school fundraisers,' she confessed, 'but now it's my go-to whenever I feel overwhelmed.' The temporary relief is quickly replaced by sleepless nights, anxiety and guilt she carries into every parent-teacher meeting. Don't get me wrong: these women aren't 'bad people' or sad caricatures of their younger selves. They are accomplished, intelligent and loving individuals caught in the same cultural trap: the allure of a quick fix, a temporary high to numb the stress and fear of midlife. But the price they're paying is steep. Physically, the signs are impossible to ignore. Cocaine's damage doesn't discriminate between genders. It steals your glow, accelerates wrinkles and leaves your body crying out for rest. (Honestly, even just one martini can do that to me these days, let alone anything stronger!) Emotionally, the toll is even worse. Relationships fray, trust erodes and self-esteem takes a nosedive. So, why do they keep doing it? The same reasons men do: to escape, to feel alive, to cling to the illusion of youth. But as we all know, illusions shatter. As I reflect on the women I once idolised for their effortless charm and unshakable confidence, I can't help but feel sadness. They deserve better. We all do. So maybe it's time to say bon voyage to 'those' kinds of bags, ladies, and invest in ones that last. Like a Birkin. It might even end up being cheaper in the long term - and it'll definitely go better with the outfit. Instagram Ozempic Gwyneth Paltrow Jana Hocking Share or comment on this article: A desperate confession in my group chat shows the 'mummy cocaine' trend has gone too far. JANA HOCKING reveals what this very middle-class epidemic has done to the women she once adored e-mail Add comment

Killing of UnitedHealthcare CEO spotlights complex challenge companies face in protecting top brass- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (LSE/STO/Nasdaq: AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over as sponsor of Achilles' Material Acquisition Platform (MAP), and receive tumor samples and data collected thus far. MAP is a proprietary network that has collected donor tumor tissue and blood from nearly 300 cancer patients undergoing standard-of-care cancer surgery across multiple solid tumor indications, including lung, melanoma, head and neck, renal, bladder, and breast. "We are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets,” said Dr Iraj Ali, CEO of Achilles Therapeutics. "We believe that these assets have the potential to positively impact Oncology R&D and will support the development of new and improved therapies for cancer patients.” AstraZeneca has agreed to pay Achilles Therapeutics $12M for the assets in total. BofA Securities provided strategic financial advice to Achilles for the transaction. Completion of this transaction signals the conclusion of Achilles' strategic review which was announced in September 2024. Achilles now plans to undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors, while remaining compliant with Nasdaq and SEC requirements. About Achilles Therapeutics Achilles is a clinical-stage biopharmaceutical company that has been developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles has used DNA sequencing data from each patient, together with its proprietary PELEUS TM bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens. About TRACERx TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at UCL, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. TRACERx has transformed the understanding of tumor evolution and has convincingly shown that tumors originate from a single cell that evolves in a Darwinian manner and the early (clonal) mutations are preserved in all subsequent primary and metastatic tumor cells. The study, which has generated numerous publications, uncovered important mechanisms of cancer evolution and immune evasion by analyzing genetic signatures in lung tumors and tracking how they evolve over time from diagnosis through to relapse. These findings provide the ability to identify a novel class of tumor markers called clonal neoantigens that are present on all tumor cells yet absent from healthy tissue, making them ideal cancer targets. TRACERx represents the largest investment in lung cancer research by Cancer Research UK. Forward Looking Statements This press release contains express or implied forward-looking statements that are based on the Company management's belief and assumptions and on information currently available to the Company's management. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company's clinical trials and the Company's beliefs about its goals for the discontinued trials; expectations related to the Company's cash runway and operating expenses and capital expense requirements; the Company's ability to engage with third parties who are developing alternative modalities to target clonal neoantigens for the treatment of cancers and the Company's review and evaluation of potential strategic options and their impact on stockholder value. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or the Company's future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent the Company's views as of the date of this press release. We anticipate that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release. For further information, please contact: Meru Advisors Lee M. Stern [email protected]